SYDNEY, N.S. —
Stylists and salon owners in Nova Scotia now know what new regulations could be put in place to reopen after being closed due to COVID-19 public health prevention measures.
The regulations were outlined during a video conference hosted by the Cosmetology Association of Nova Scotia on Thursday, which they said are in the process of being reviewed by Nova Scotia’s chief medical officer Robert Strang. Strang must give approval before they are implemented.
These regulations dictate all staff and clients must wear masks at all times. Staff can choose to wear a face shield instead.
There will be no waiting rooms (clients have to stay in their cars until receiving a text they can come in), no magazines to look at and no drinks available for clients.
If there can’t be six feet between workstations or sinks, a Plexiglas divider must be installed. All reception desks also need a Plexiglas shield and customers can’t touch retail items until after purchase.
The regulations also forbid double booking clients — a common practice in the beauty industry which allows a stylist to work on more than one client at a time. While one client’s colour is setting, a stylist could start another or do a cut, which increases their earning potential. Estheticians could also start a new customer’s nails while the previous one has dried — but with no waiting rooms, they can’t.
This inevitable loss in revenue is causing concern for many in the industry, despite their eagerness to get back to work.
“When you’re working and you’re used to working on three or four clients at a time, taking it down to one is going to be hard,” said Alma Head, owner of two Alma’s Family Hair Salon and Tanning locations.
“That’s going to be a little hard for the profits. Hairdressers live off of double bookings… No customers means no money but hopefully in a few months it can go back to our new normal, whatever that is.”
Tracie Breski, owner of Tracie’s Salon and Spa in Sydney, also admitted she was a bit concerned about the loss of revenue for her and her staff.
“We will be working with half the volume of clients we were dealing with before,” said Breskie, who’s been in the industry for 30 years. “It was suggested we raise our prices to offset the loss of revenues and the increase in overhead, but my goal wouldn’t be to put that responsibility back on the client… It’s not their fault this happened.”
Head also thinks raising prices isn’t feasible.
“Unless the $80 colour turns into a $200 colour, we can’t raise our prices enough to cover the losses,” she said, noting she hopes the regulations will relax in a few months.
“At the end of the week, you’re going to have some stylists asking is this worth it… If it continues like this, we’re going to see a lot of people leaving this industry.”
Challenges aside, both salon owners said they were motivated by the video conference, eager to reopen and happy to learn what they’d need to do before getting back to business.
Head, a stylist for more than 30 years, has already started renovating her two salons (in New Waterford and Sydney) estimates it will cost $10,000. Breski is starting to work out the details for her Sydney salon, determining what can be moved to keep six feet (two metres) in between stations and sourcing quotes for Plexiglas dividers. She also estimates costs for her will be “in the thousands” to get the work done.
However, both are determined to get back to business and make the new style of services work. Focusing on the positives, both stress their main priority is keeping their staff and clients safe and they plan to follow all regulations by the book. At the end of the day, they just want to be working again.
“I love the spa. I love it,” said Breski. “I love going there. I love the staff. I love the clients. It’s our family. This has all be hard emotionally.”
Public health working to contain latest COVID-19 outbreaks – WellandTribune.ca
'No benefit' from hydroxychloroquine for virus: UK trial – The Jakarta Post – Jakarta Post
A major British clinical trial has found hydroxychloroquine has “no benefit” for patients hospitalized with COVID-19, scientists said Friday, in the first large-scale study to provide results for a drug at the center of political and scientific controversy.
Hydroxychloroquine, a decades-old malaria and rheumatoid arthritis drug, has been touted as a possible treatment for the new coronavirus by high profile figures, including US President Donald Trump, and has been included in several randomized clinical trials.
The University of Oxford’s Recovery trial, the biggest of these so far to come forward with findings, said that it would now stop recruiting patients to be given hydroxychloroquine “with immediate effect”.
“Our conclusion is that this treatment does not reduce the risk of dying from COVID among hospital patients and that clearly has a significant importance for the way patients are treated, not only in the UK, but all around the world,” said Martin Landray, an Oxford professor of medicine and epidemiology who co-leads the study.
The randomized clinical trial—considered the gold standard for clinical investigation—has recruited a total of 11,000 patients from 175 hospitals in the UK to test a range of potential treatments.
Other drugs continuing to be tested include: the combination of HIV antivirals Lopinavir and Ritonavir; a low dose of the steroid Dexamethasone, typically used to reduce inflammation; antibiotic Azithromycin; and the anti inflammatory drug Tocilizumab.
Researchers are also testing convalescent plasma from the blood of people who have recovered from COVID-19, which contains antibodies to fight the virus.
Researchers said 1,542 patients were randomly assigned to hydroxychloroquine and compared with 3,132 patients given standard hospital care alone.
They found “no significant difference” in mortality after 28 days between the two groups, and no evidence that treatment with the drug shortens the amount of time spent in hospital.
“This is a really important result, at last providing unequivocal evidence that hydroxychloroquine is of no value in treatment of patients hospitalized with COVID-19,” said Peter Openshaw, a professor at Imperial College London, in reaction to the results.
He added that the drug was “quite toxic” so halting the trials would be of benefit to patients.
Hydroxychloroquine has been in use for years but it has a number of potentially serious side effects, including heart arrhythmia.
Researchers from the Recovery trial said they would share their data with the World Health Organization (WHO), which on Wednesday restarted its own trials of hydroxychloroquine.
They were temporarily halted last month because of a now-retracted observational study in The Lancet medical journal that had suggested hydroxychloroquine and chloroquine, a related compound, were ineffective against COVID-19 and even increased the risk of death.
Authors of The Lancet research said on Thursday that they could no longer vouch for the integrity of its underlying data, in the face of serious concerns raised by fellow scientists over a lack of clarity about the countries and hospitals that contributed patient information.
The scandal cast a shadow over The Lancet and another top medical journal, but it did nothing to clear up the increasingly politicized question of whether or not hydroxychloroquine works as a treatment for COVID-19.
Openshaw said the Recovery trial should be credited with continuing the research until they could reach a definitive conclusion on hydroxychloroquine.
“Everyone regrets that it doesn’t work, but knowing that allows us to focus on finding drugs that actually help recovery from COVID-19,” he added.
Oxford professor Peter Horby, the lead investigator on the Recovery Trial, said there was probably a “very large number” of people around the world taking hydroxychloroquine for COVID-19, with countries including the US, China and Brazil authorizing it.
A separate clinical trial on Wednesday in the US and Canada found that taking hydroxychloroquine shortly after being exposed to COVID-19 does not work to prevent infection significantly better than a placebo.
If you want to help in the fight against COVID-19, we have compiled an up-to-date list of community initiatives designed to aid medical workers and low-income people in this article. Link: [UPDATED] Anti-COVID-19 initiatives: Helping Indonesia fight the outbreak
No new coronavirus cases in Manitoba on Saturday – Globalnews.ca
Manitoba health officials say there are no new cases of the coronavirus identified as of Saturday morning.
Health officials say the total number of lab-confirmed positive and probable cases in the province remains at 300.
There are nine active cases as of Friday and 284 individuals who have recovered from COVID-19.
The number of deaths due to COVID-19 remains at seven.
© 2020 Global News, a division of Corus Entertainment Inc.
McGregor retires from fighting – TSN
Public health working to contain latest COVID-19 outbreaks – WellandTribune.ca
Small asteroid to safely fly by Earth on Saturday – SHINE
- Tech10 hours ago
New release date for Call of Duty: Modern Warfare Season 4 has been leaked – PCGamesN
- Sports18 hours ago
Donald Trump says Drew Brees shouldn't have backed off flag comments – CBC.ca
- Tech17 hours ago
iOS 14 roundup: What we know before WWDC 2020 – 9to5Mac
- Economy9 hours ago
Guardians of the World Economy Stagger From Rescue to Recovery – Yahoo Canada Finance
- Tech24 hours ago
New Redmi 9 alleged prices are ridiculously cheap for a smartphone with a quad-camera setup and 8-core MediaTek Helio G80 SoC – Notebookcheck.net
- Economy21 hours ago
Don’t Lose the Thread. The Economy Is Experiencing an Epic Collapse of Demand. – The New York Times
- Tech1 hour ago
Call of Duty Modern Warfare Season 4 release: Is this when Warzone Season 4 comes out? – Express
- Tech23 hours ago
Apple iOS 13.5.5 Can’t Come Soon Enough: Here Are 3 Reasons Why – Forbes